Home › Companies › LARIMAR THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and LARIMAR THERAPEUTICS INC.’s Form 8-K, filed May 13, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 13, 2025: 3 items on LARIMAR THERAPEUTICS INC.’s Form 8-K, filed May 13, 2025: 1 elected · 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore LARIMAR THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are LARIMAR THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Thomas E. Hamilton | 46,479,322 | -- | -- | 4,326,129 | 6,865,481 | 91% | Elected | — |
| 2. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2024 | 49,187,132 | 1,445,631 | 172,688 | -- | 6,865,481 | 97% | Approved | — |
| 3. Ratification of Independent Registered Public Accountant | 57,657,322 | 10,851 | 2,759 | -- | 0 | 99.9% | Approved | — |
Source: LARIMAR THERAPEUTICS INC., Form 8-K, filed with the SEC on May 13, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
109 asset managers disclosed a vote on at least one LARIMAR THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
91% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF CLASS II DIRECTOR FOR A THREE-YEAR TERM EXPIRING IN 2028: THOMAS E. HAMILTON
LARIMAR THERAPEUTICS INC.’s own tally for this item (“Elect Director: Thomas E. Hamilton”): 46,479,322 for, 4,326,129 withheld, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Thomas E. Hamilton was elected to the Board of Directors of the Company as a Class II director to serve until the Company's 2028 Annual Meeting of Stockholders and until his successor, if any, is duly elected and qualified or appointed, or his earlier death, resignation, or removal, as follows:”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 3,906,122 for, 826,451 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,587,956 | 0 | 0 | 37,029 | For |
| Vanguard | 1,494,271 | 0 | 0 | 0 | For |
| Fidelity | 692,304 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 164,215 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 100,457 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 96,916 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 70,068 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 63,904 | Withhold |
| Equitable | 23,314 | 0 | 0 | 33,060 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 48,282 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 31,200 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 26,869 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 26,037 | Withhold |
| Global X | 0 | 0 | 0 | 25,209 | Withhold |
| Northern Trust | 0 | 0 | 0 | 22,360 | Withhold |
| Dimensional | 0 | 0 | 0 | 21,565 | Withhold |
| Nationwide | 11,509 | 0 | 0 | 9,544 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 20,609 | Withhold |
| John Hancock | 0 | 0 | 0 | 16,157 | Withhold |
| State Street | 0 | 0 | 0 | 15,923 | Withhold |
| Pacific Life | 14,574 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 12,761 | Withhold |
| Voya | 0 | 0 | 0 | 12,092 | Withhold |
| Bridge Builder Trust | 8,134 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 6,900 | Withhold |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 95.4% for (May 29, 2024 meeting) ▲ 1.7 pts
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS IN 2024
LARIMAR THERAPEUTICS INC.’s own tally for this item (“2. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2024”): 49,187,132 for, 1,445,631 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers in 2024, as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,624,985 | 0 | 0 | 0 | For |
| Vanguard | 1,494,271 | 0 | 0 | 0 | For |
| Fidelity | 692,304 | 0 | 0 | 0 | For |
| TIAA | 164,215 | 0 | 0 | 0 | For |
| Charles Schwab | 100,457 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 96,916 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 70,068 | 0 | 0 | 0 | For |
| American Century | 0 | 63,904 | 0 | 0 | Against |
| Equitable | 56,374 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,282 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,200 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 26,869 | 0 | 0 | 0 | For |
| Goldman Sachs | 26,037 | 0 | 0 | 0 | For |
| Global X | 25,209 | 0 | 0 | 0 | For |
| Northern Trust | 22,360 | 0 | 0 | 0 | For |
| Dimensional | 21,565 | 0 | 0 | 0 | For |
| Nationwide | 21,053 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,609 | 0 | 0 | 0 | For |
| John Hancock | 16,157 | 0 | 0 | 0 | For |
| State Street | 15,923 | 0 | 0 | 0 | For |
| Pacific Life | 14,574 | 0 | 0 | 0 | For |
| ProShares | 12,761 | 0 | 0 | 0 | For |
| Voya | 12,092 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,134 | 0 | 0 | 0 | For |
| SEI | 6,900 | 0 | 0 | 0 | For |
Fund voting reports, all 36 managers: 4,567,632 for, 164,941 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. | 21,231,974 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 5,709,058 | 0 | 0 | 0 | For |
| Janus Henderson | 4,820,042 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 4,753,040 | 0 | 0 | 0 | For |
| BlackRock | 1,049,198 | 129 | 0 | 0 | For |
| Goldman Sachs | 904,593 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 0 | 850,631 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 765,092 | 0 | 0 | 0 | For |
| Woodline Partners LP | 622,682 | 0 | 0 | 0 | For |
| State Street | 606,059 | 181 | 0 | 0 | For |
| Opaleye Management Inc. | 550,000 | 0 | 0 | 0 | For |
| Citadel | 459,283 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 371,434 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 355,995 | 0 | 0 | 0 | For |
| Point72 | 254,384 | 0 | 0 | 0 | For |
| Northern Trust | 208,625 | 0 | 0 | 0 | For |
| Two Sigma | 204,565 | 0 | 0 | 0 | For |
| Nuveen | 174,788 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 138,965 | 0 | 0 | 0 | For |
| UBS | 138,602 | 0 | 0 | 0 | For |
| Renaissance | 106,908 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 103,216 | 0 | 0 | Against |
| Charles Schwab | 100,457 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 87,527 | 0 | 0 | 0 | For |
| American Century | 0 | 63,904 | 0 | 0 | Against |
Institutional-manager reports, all 87 managers: 43,967,179 for, 1,068,225 against, 137 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (May 29, 2024 meeting) unchanged
Description as filed by funds: Ratification of Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm for the 2025 Fiscal Year
LARIMAR THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Independent Registered Public Accountant”): 57,657,322 for, 10,851 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2025 fiscal year was ratified, as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 4,732,573 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,624,985 | 0 | 0 | 0 | For |
| Vanguard | 1,494,271 | 0 | 0 | 0 | For |
| Fidelity | 692,304 | 0 | 0 | 0 | For |
| TIAA | 164,215 | 0 | 0 | 0 | For |
| Charles Schwab | 100,457 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 96,916 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 70,068 | 0 | 0 | 0 | For |
| American Century | 63,904 | 0 | 0 | 0 | For |
| Equitable | 56,374 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,282 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,200 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 26,869 | 0 | 0 | 0 | For |
| Goldman Sachs | 26,037 | 0 | 0 | 0 | For |
| Global X | 25,209 | 0 | 0 | 0 | For |
| Northern Trust | 22,360 | 0 | 0 | 0 | For |
| Dimensional | 21,565 | 0 | 0 | 0 | For |
| Nationwide | 21,053 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,609 | 0 | 0 | 0 | For |
| John Hancock | 16,157 | 0 | 0 | 0 | For |
| State Street | 15,923 | 0 | 0 | 0 | For |
| Pacific Life | 14,574 | 0 | 0 | 0 | For |
| ProShares | 12,761 | 0 | 0 | 0 | For |
| Voya | 12,092 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,134 | 0 | 0 | 0 | For |
| SEI | 6,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,027,892 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 2.54% |
| 2 | Vanguard | 2.33% |
| 3 | Fidelity | 1.08% |
| 4 | TIAA | 0.26% |
| 5 | Charles Schwab | 0.16% |
| 6 | BRIDGEWAY FUNDS INC | 0.15% |
| 7 | QUANTITATIVE MASTER SERIES LLC | 0.11% |
| 8 | American Century | 0.10% |
| 9 | Equitable | 0.09% |
| 10 | ALPS ETF Trust | 0.08% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | DEERFIELD MANAGEMENT COMPANY, L.P. | 33.16% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8.92% |
| 3 | Janus Henderson | 7.53% |
| 4 | Blue Owl Capital Holdings LP | 7.42% |
| 5 | BlackRock | 1.64% |
| 6 | Goldman Sachs | 1.41% |
| 7 | Alyeska Investment Group, L.P. | 1.33% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.19% |
| 9 | Woodline Partners LP | 0.97% |
| 10 | State Street | 0.95% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Deerfield Management Company, L.P. | 35,667,474 | 55.71% | Schedule 13D, filed March 2, 2026 |
| Opaleye Management, Inc. | 4,110,000 | 6.42% | Schedule 13G, filed August 29, 2025 |
| BlackRock | 3,123,988 | 4.88% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 2,671,271 | 4.17% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 2,217,808 | 3.46% | Form 13F, quarter ended March 31, 2025 |
| Renaissance Technologies | 974,971 | 1.52% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 907,961 | 1.42% | Form 13F, quarter ended March 31, 2025 |
| State Street | 832,541 | 1.30% | Form 13F, quarter ended March 31, 2025 |
| Millennium Management | 673,012 | 1.05% | Form 13F, quarter ended March 31, 2025 |
| Citadel Advisors | 501,086 | 0.78% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 64,027,892 shares outstanding, as reported by LARIMAR THERAPEUTICS INC. on its Form 10-Q dated April 27, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At LARIMAR THERAPEUTICS INC.'s shareholder meeting held May 13, 2025, in the 2024-2025 proxy season, 109 asset managers reported votes on at least one of its 3 ballot items in their SEC Form N-PX filings, covering 410 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS IN 2024 — LARIMAR THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: LARIMAR THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 13, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LARIMAR THERAPEUTICS INC.’s 10-Q dated April 27, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
LARIMAR THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “LARIMAR THERAPEUTICS (LRMR) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/larimar-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.